The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.
about
EGFR/HER-targeted therapeutics in ovarian cancerMeasurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagentsThe dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90.Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsThe epidermal growth factor receptor family in breast cancer.Primary trastuzumab resistance: new tricks for an old drug.Preoperative serum HER2 extracellular domain levels in primary invasive breast cancerp185, an immunodominant epitope, is an autoantigen mimotope.Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.HER2 therapy: molecular mechanisms of trastuzumab resistance.The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinomaClinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancersA truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer.Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.C-terminal truncated forms of Met, the hepatocyte growth factor receptorA naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragmentSignalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.
P2860
Q26863231-CD72466E-8CF0-46EA-892F-D01956046FC1Q28535487-9EBFA6C9-4F61-479F-AF73-2F370586587AQ33676854-9A3A38BA-12B0-41A6-AB75-7B2C561E1CA8Q33809397-42DB84DF-4111-4687-91F0-7E1C682C1EDFQ33812042-F1B7EE73-D585-4450-9302-00E96CB46C2CQ34363400-95F667EC-668F-44CD-9CA1-D9A630E660E6Q34610251-4D321A76-E931-4A64-BC18-6917CDFD5739Q34967515-396DE00C-2732-44C8-952F-967450F3C597Q35110970-B0CA7F68-386E-498F-8968-DDBFE569510DQ35527141-7B532C81-1D06-43D9-B69A-2AA9F754CE30Q35633712-70CC8F92-0220-4236-9983-EEBD736C79FAQ36092023-C92F360F-E00C-4F76-BF07-02C31960AD54Q36106412-ED696ED2-8AAD-466A-BF9F-5F5F2F0E714CQ36141019-5A962497-717D-4AB6-BD63-E237BE82B7A1Q36205260-E275E71A-8C07-48CA-A147-4CD2ED210074Q36335248-AF8E5E45-E1B2-481F-A423-1A116484E84AQ36421735-73B4B14A-1054-4A7D-8EDF-4C1E9DAE8B03Q36591915-B87601C8-1A1C-4818-B4A8-92BF10929B75Q36671789-8AF79E58-603F-4AE9-9388-9CC7E2451118Q36678230-0E9FF6A8-6DED-441F-8D4C-C378F23A3A56Q36695530-0BE2A9B1-1720-414F-ACCD-12CB222F95D1Q36727464-1E702E08-C31C-47F5-A0F5-D455F7547DFEQ36743037-52BD0EB7-E11A-4CE4-8775-4A1C5256CDF0Q37233360-ABB757F9-BC07-476D-9AB7-7BB25A4A2667Q37332545-7DF5CD66-4D06-45DC-A643-EB44F7439FEDQ37341686-7BBBD08D-777A-4F52-A8C9-7729D0BF360CQ38673589-7DBF130A-B9BA-4351-B15A-1CEB7E7EBD31Q41233767-653D78D4-D60A-4861-9C3D-E864954BA278Q41967579-9C87A2BF-F579-4044-9750-25D67C0F25FAQ55075802-1AA8A381-8AB0-4D3A-8F5E-60E751C8F2B1Q55078620-E07F15F7-DAAE-4AC8-A99C-4F98CE32EE72
P2860
The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
The extracellular domain of p1 ...... east carcinoma cells, SK-BR-3.
@en
type
label
The extracellular domain of p1 ...... east carcinoma cells, SK-BR-3.
@en
prefLabel
The extracellular domain of p1 ...... east carcinoma cells, SK-BR-3.
@en
P2093
P1476
The extracellular domain of p1 ...... east carcinoma cells, SK-BR-3.
@en
P2093
P304
P407
P577
1991-01-01T00:00:00Z